BNP Paribas Downgrades Sanofi to Neutral
Key Questions
Why did BNP Paribas downgrade Sanofi?
BNP Paribas downgraded Sanofi (SNY) to Neutral from Outperform due to views on its pipeline. Analyst Peter Verdult cited these concerns in the downgrade.
What is BNP Paribas' new price target for Sanofi?
BNP Paribas lowered its price target for Sanofi to $50 from $59. This follows the downgrade to Neutral from Outperform.
How does BNP Paribas' rating on Sanofi compare to other analysts?
BNP Paribas' Neutral rating contrasts with the average overweight rating for Sanofi. The mean price target from analysts is $54.32, suggesting mixed signals that could lead to short-term volatility.
BNP cut to Neutral from Outperform, PT $50 from $59 on pipeline views; contrasts overweight avg. Mixed analyst signals could spark short-term downside volatility.
Sources (2)
Updated Apr 26, 2026